Defining the complex phenotype of severe systemic loxoscelism using a large electronic health record cohort

Jamie R. Robinson¹,²*, Vanessa E. Kennedy³, Youssef Doss⁴, Lisa Bastarache¹,
Joshua Denny¹,⁵, Jeremy L. Warner¹,⁵

¹ Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, United States of America, ² Department of General Surgery, Vanderbilt University Medical Center, Nashville, TN, United States of America, ³ Department of Internal Medicine, Stanford University, Stanford, CA, United States of America, ⁴ Yale University, New Haven, CT, United States of America, ⁵ Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States of America

* jamie.r.robinson@vanderbilt.edu

Abstract

Objective

Systemic loxoscelism is a rare illness resulting from the bite of the recluse spider and, in its most severe form, can lead to widespread hemolysis, coagulopathy, and death. We aim to describe the clinical features and outcomes of the largest known cohort of individuals with moderate to severe loxoscelism.

Methods

We performed a retrospective, cross sectional study from January 1, 1995, to December 31, 2015, at a tertiary-care academic medical center, to determine individuals with clinical records consistent with moderate to severe loxoscelism. Age-, sex-, and race-matched controls were compared. Demographics, clinical characteristics, laboratory measures, and outcomes of individuals with loxoscelism are described. Case and control groups were compared with descriptive statistics and phenome-wide association study (PheWAS).

Results

During the time period, 57 individuals were identified as having moderate to severe loxoscelism. Of these, only 33% had an antecedent spider bite documented. Median age of individuals diagnosed with moderate to severe loxoscelism was 14 years old (IQR 9.0–24.0 years). PheWAS confirmed associations of systemic loxoscelism with 29 other phenotypes, e.g., rash, hemolytic anemia, and sepsis. Hemoglobin level dropped an average of 3.1 g/dL over an average of 2.0 days (IQR 2.0–6.0). Lactate dehydrogenase and total bilirubin levels were on average over two times their upper limit of normal values. Eighteen individuals of 32 tested had a positive direct antiglobulin (Coombs’) test. Mortality was 3.5% (2/57 individuals).
Conclusion
Systemic loxoscelism is a rare but devastating process with only a minority of patients recalling the toxic exposure; hemolysis reaches a peak at 2 days after admission, with some cases taking more than a week before recovery. In endemic areas, suspicion for systemic loxoscelism should be high in individuals, especially children and younger adults, presenting with a cutaneous ulcer and hemolysis or coagulopathy, even in the absence of a bite exposure history.

Introduction
Systemic loxoscelism is a constitutional illness resulting from the bite of spiders of the genus Loxosceles, which is distributed worldwide. In parts of the United States, the Loxosceles reclusa, commonly referred to as the brown recluse spider, is endemic. Such bites commonly cause local necrosis, referred to as necrotic arachnoidism.[1] Systemic toxicity may also occur and in its mild form consists of nausea, vomiting, fever, chills, or arthralgia. In its more severe form, brown recluse bites may cause massive hemolysis, hemoglobinuria, acute renal failure, disseminated intravascular coagulation, and rarely death.[2–5] The most significant morbidity in systemic loxoscelism results from hemolysis and coagulopathy.[6, 7] Because hemolysis resulting from loxoscelism is uncommon, there is little known about its clinical manifestations, diagnosis, or outcomes.[8] Use of dapsone, once considered a treatment for systemic loxoscelism, has declined due to the suggestion of increased risk of hemolysis.[9] The underlying pathogenesis of systemic loxoscelism remains incompletely understood, but sphingomyelinase D, a component of the venom toxin, has been shown to have a central role in the process.[10–12] Recent literature suggests it causes both direct toxin-mediated hemolysis and complement-mediated erythrocyte destruction.[8, 11, 13] There is also an indication that hemolysis may be partly immune-mediated, given that a certain proportion of individuals reported in the literature have shown positive direct antiglobulin testing (DAT; Coombs') for surface immunoglobulin G (IgG).[7]

The majority of brown recluse spider bite victims lack systemic symptoms, and severe systemic symptoms are even more rare.[14] In 2014, only 1,330 brown recluse spider bites were reported in the United States; of these, 481 individuals required treatment in a health care facility.[15] The brown recluse spider is endemic to the southeastern and Midwestern United States, and likelihood of envenomation outside of these areas is extremely low.[16, 17] Due to the limited geographic nature of the brown recluse and infrequent occurrence of systemic loxoscelism, there is little published on the clinical features and outcomes of these individuals.

In this study, we describe clinical characteristics and outcomes of the largest known cohort of individuals with systemic loxoscelism to date, leveraging our large de-identified electronic clinical data warehouse. We then performed a phenome-wide association study (PheWAS) of these individuals matched to a control population to identify key differences in ~1800 phenotypes between individuals who develop systemic loxoscelism and those who do not. PheWAS has previously been successfully applied to genomic and laboratory results with high validity to replicate known associations.[18–21] Our goal was to highlight clinical characteristics of this rare and potentially lethal illness, and to potentially uncover previously undocumented phenotypic associations.

Materials and methods
A retrospective, cross-sectional study was performed to analyze suspected cases of loxoscelism at Vanderbilt University Medical Center (VUMC), a tertiary-care academic medical
center, over a 20-year time span. VUMC consists of an adult and children’s hospital in the epicenter of the brown recluse geographical range.[17] Data collection was performed using the VUMC Synthetic Derivative (SD), a de-identified version of over 2.4 million patient electronic health records.[22] Dates are shifted at random +/- 365 days for each individual with relative time preservation. We identified all records with shifted dates between January 1st, 1995 and December 31st, 2015 containing any mention of “loxoscelism” in a clinical note, problem list, discharge summary, clinical communication, or letter. A two-person manual review of all flagged records was performed, and discrepancies were adjudicated by a third reviewer. This study was approved and designated as non-human subject research by the Institutional Review Board of Vanderbilt University Medical Center; therefore, consent was not necessary.

Individuals were manually excluded from the study if they lacked evidence of systemic loxoscelism, i.e., absence of fever, chills, abdominal pain, hemolysis or abnormal liver function tests. Individuals with moderate to severe loxoscelism were determined by the presence of a documented diagnosis of hemolysis or disseminated intravascular coagulation, need for blood transfusion, or hemodynamic instability.

Control individuals were extracted to be age-, sex-, and race-matched to the cases with a 50:1 control to case ratio.

Variable data extracted included demographics and clinical parameters, including length of hospital stay, intensive care unit (ICU) admission, need for hemodialysis, and mortality. Race was self-reported and extracted for population comparisons and matching of controls. We determined individuals who received dapsone prior to or during admission to VUMC. The presence of a toxicology consultation and/or operative intervention for the cutaneous lesion, if present, were also documented. Laboratory values obtained included hemoglobin (HGB), lactate dehydrogenase (LDH), total bilirubin, haptoglobin, creatinine, urinalysis, and DAT. We selected for laboratory data 1 week prior to and up 3 weeks after the first instance of either “loxoscelism” in a clinical document or ICD-9-CM billing code of 989.5 (toxic effect of venom). Descriptive statistics were performed, including mean or median with interquartile ranges for continuous variables or frequencies and percentages for categorical variables. Demographic differences between case and control groups were assessed using Chi-square or Fisher exact test, as appropriate. Wilcoxon rank sum test was used to compare ages of individuals with moderate-severe systemic loxoscelism to those with only cutaneous or mild systemic symptoms. PheWAS of cases versus controls was applied. PheWAS codes are aggregations of ICD-9-CM codes, as previously described.[19] All pairwise PheWAS comparisons were conducted using logistic regression with adjustment for age and sex. The minimum number of records to perform a test was 20 individuals in the combined case and control groups, with each individual having at least 2 instances of the PheWAS code. All statistical analyses were performed with R statistical software[23] using the PheWAS package and PheWAS code map version 1.2.[21]

**Results**

The initial search found 373 possible cases with “loxoscelism” documented within the SD. After manual review and exclusion of subjects due to the lack of systemic loxoscelism, 57 individuals with moderate to severe loxoscelism were included in the final analysis. Of the excluded individuals, 90 were found to have cutaneous-only symptoms consistent with brown recluse spider bite, and 58 individuals had mild symptoms of systemic loxoscelism; the remainder had negation terms for loxoscelism (e.g., “this presentation is not consistent with loxoscelism.”). The control cohort consisted of 2,850 individuals.
Demographic characteristics

Of the individuals identified, 54% were female and the majority Caucasian (37/57 individuals, 65%). A significantly larger portion of those with loxoscelism was African American (26%) compared to the SD population of ever-admitted individuals (15% African American \( p = 0.02 \)).

The ages of those with moderate to severe loxoscelism were highly skewed towards children and young adults with 82.5% (47/57) of subjects under 30 years of age (Fig 1). The median age of included individuals was 14 years old (IQR 9.0–24.0 yrs), significantly younger \( (p = 2.0 \times 10^{-7}) \) than the median age of those identified with only cutaneous or mild systemic symptoms \( (n = 148, \text{median age 30 years old [IQR 19.0–46.0 yrs]}) \). Admitted SD individuals were also on average older than those with loxoscelism \( (n = 667,990, \text{median age 33 years old [IQR 12.0–58.0 yrs]}) \).

All individuals presented with a cutaneous ulcer consistent with a brown recluse spider bite, but many did not recall an antecedent spider bite. According to the documentation present in the SD, only 33% (19 of 57) witnessed the spider and confirmed site of a brown recluse at the time of the envenomation. Ulcer location was most commonly on the upper extremity \( (27 \text{ of 57 individuals, 47%}) \) or lower extremity \( (10 \text{ of 57 individuals, 18%}) \). Further demographics and clinical characteristics are in Table 1.

Clinical parameters

Laboratory parameters during the period with loxoscelism are in Table 1. Average HGB level at presentation was below normal \( (\text{median } 10.2 \text{ g/dL, reference } 11.8–16.0) \). Furthermore, the average lowest HGB per case was significantly below normal \( (8.7 \text{ g/dL, IQR 5.7–10.5}) \). HGB decreased after admission in most individuals but gradually increased back to baseline, with or without supportive transfusion (Fig 2 Parts A-B). Relative decline in HGB was more severe for those admitted or transferred to the ICU during their hospitalization, compared to non-ICU areas. Not including the 12 individuals that arrived with their lowest recorded HGB, HGB level dropped an average of 3.1 g/dL from the first recorded level over an average of 2.0 days (IQR 2.0–6.0). There were 9 individuals with a decline in HGB of over 6 g/dL, of which 6 \( (67\%) \) occurred 5–8 days after the first recorded value.

LDH \( (529.0 \text{ unit/L, reference } < 226 \text{ unit/L}) \) and total bilirubin \( (2.9 \text{ mg/dL, reference } 0.2–1.2 \text{ mg/dL}) \) were over two times their normal values. Median haptoglobin and creatinine levels were within normal range. Of the entire cohort, 32 individuals underwent DAT testing and 18 \( (56\%) \) showed positivity. Of the 18 individuals with a positive DAT test, 9 \( (50\%) \) were positive for C3 and IgG, 6 \( (33\%) \) were positive for only IgG and 3 \( (17\%) \) positive only for C3.

PheWAS for loxoscelism phenotype

A PheWAS for phenotypic associations with loxoscelism revealed many strong correlations including rash \( (p = 1.8 \times 10^{-28}) \), toxic effect of venom \( (p = 1.5 \times 10^{-26}) \), and hemolytic anemia \( (p = 2.0 \times 10^{-27}) \), which were also the most frequent phenotypes associated with individuals with loxoscelism (Fig 3 Parts A-B). These were clinical parameters used to assist in confirming the loxoscelism phenotype. Phenotypes that align with intravascular hemolysis, including coagulation defects \( (p = 2.3 \times 10^{-16}) \), hematuria \( (p = 3.1 \times 10^{-14}) \), and thrombocytopenia \( (1.1 \times 10^{-6}) \), were also strongly associated. The PheWAS analysis found strong associations between loxoscelism and superficial cellulitis/abscess \( (p = 2.1 \times 10^{-23}) \), sepsis \( (p = 3.1 \times 10^{-18}) \), and septicemia \( (p = 6.7 \times 10^{-12}) \), all possible correlations with infection. All statistically significant associations are in Table 2.
Fig 1. Cumulative Distribution of Cases by Age. Each point represents a case of either moderate-severe (mod-severe, red) loxoscelism or cutaneous/mild loxoscelism (cutaneous or mild, blue). The cumulative proportions of patients at or under a specific age are represented by each line. The median age of individuals with severe loxoscelism (14 years, IQR 9.0–24.0 yrs), was significantly lower than the median age (30 years old, IQR 19.0–46.0 yrs) of those identified with only cutaneous or mild systemic symptoms ($p = 2.0 \times 10^{-7}$).

https://doi.org/10.1371/journal.pone.0174941.g001
### Treatment and outcomes

Clinical outcomes for individuals are reported in Table 1. All individuals were hospitalized except for one who died in the Emergency Department. The median length of hospital stay

---

**Table 1. Clinical characteristics and outcomes of systemic loxoscelism.**

|                      | Loxoscelism Cohort (n = 57) | Reference |
|----------------------|-----------------------------|-----------|
| **Age, median (IQR)**| 14.0 (9.0–24.0)              | -         |
| **Sex, No. (%)**     |                             | -         |
| Male                 | 26 (46%)                    | -         |
| Female               | 31 (54%)                    | -         |
| Unknown              | 0 (0%)                      | -         |
| **Race, No. (%)**    |                             | -         |
| White                | 37 (65%)                    | -         |
| African American     | 15 (26%)                    | -         |
| Asian                | 1 (2%)                      | -         |
| Unknown/Not Reported | 4 (7%)                      | -         |
| Other                | 0 (0%)                      | -         |
| **Witnessed brown recluse spider bite, No. (%)** | 19 (33%) | - |
| **Bite Location, No. (%)** |                       |           |
| Upper extremity      | 27 (47%)                    | -         |
| Lower extremity      | 10 (18%)                    | -         |
| Chest                | 6 (11%)                     | -         |
| Back                 | 6 (11%)                     | -         |
| Abdomen              | 4 (7%)                      | -         |
| Head/neck            | 3 (6%)                      | -         |
| Other                | 1 (2%)                      | -         |
| **Laboratory, median (IQR)** |                   |           |
| HGB (g/dL)           | 10.2 (8.4–11.7)             | 11.8–16.0 |
| Lowest HGB (g/dL)    | 8.7 (5.7–10.5)              | 11.8–16.0 |
| Change in HGB (n = 43, g/dL) | -3.1 (-1.8 to -5.6) | -         |
| Average time to lowest HGB (n = 43, days) | 2.0 (2.0–6.0) | -         |
| LDH (unit/L)         | 529.0 (265.5–833.5)         | <226      |
| Highest LDH per individual (n = 37, unit/L) | 739.0 (366.0–1344.0) | <226      |
| Total Bilirubin (mg/dL) | 2.9 (1.5–5.6)              | 0.2–1.2   |
| Highest Total Bilirubin (n = 47, mg/dL) | 4.3 (1.9–7.4)              | 0.2–1.2   |
| Haptoglobin (mg/dL)  | 3                           | 16–200    |
| Lowest Haptoglobin (n = 23, mg/dL) | 25.0 (2.5–129.5)          | 16–200    |
| Creatinine (mg/dL)   | 0.8 (0.6–1.0)               | 0.70–1.50 |
| Highest Creatinine (n = 54, mg/dL) | 0.9 (0.6–1.2)              | 0.70–1.50 |
| **Direct Antiglobulin positivity (n = 32), No. (%)** | 18 (56%) | Negative |
| Dapsone treatment, No. (%) | 2 (4%)                    | -         |
| Operative Intervention, No. (%) | 5 (9%)                    | -         |
| Toxicology Consult, No. (%) | 46 (80.7%)                | -         |
| ICU Admission, No. (%) | 28 (49.1%)                 | -         |
| **Length of Hospital Stay, median days (IQR)** | 4.0 (2.0–5.0)              | -         |
| Dialysis, No. (%)    | 3 (5.3%)                    | -         |
| Mortality, No. (%)   | 2 (3.5%)                    | -         |

IQR: Interquartile Range; HGB: Hemoglobin; LDH: Lactate Dehydrogenase; ICU: Intensive Care Unit

https://doi.org/10.1371/journal.pone.0174941.1001
Fig 2. Hemoglobin Fluctuation During Loxoscelism. (A) Each line represents one individual with time and hemoglobin (HGB) graphed relative to the time point at the lowest HGB level (HGB Nadir) and the highest recorded HGB for each individual. Most HGB levels decline after admission and return to baseline. (B) ICU patients have lower interquartile ranges of HGB at presentation and at the HGB nadir, as compared to non-ICU patients. By the time of hospital discharge, the relative HGB level is similar between the two populations.

https://doi.org/10.1371/journal.pone.0174941.g002
Fig 3. Phenotypes and PheWAS of Individuals with Moderate–Severe Loxoscelism. (A) Manhattan plot representing the number of individuals with moderate to severe loxoscelism with each phenotype. The most frequent phenotypes validated the loxoscelism definition and included the toxic effect of venom, acquired hemolytic anemia, fever of unknown origin, and rash/skin eruption. (B) PheWAS for moderate-severe loxoscelism. The blue line represents significance level without correction ($p = 0.05$). The red line is representative of the adjusted significance threshold using the Bonferroni correction for multiple comparisons ($p = 1.2 \times 10^{-4}$). 29 phenotypes showed a significant correlation ($p < 1.2 \times 10^{-4}$) with the loxoscelism phenotype when compared to controls.

https://doi.org/10.1371/journal.pone.0174941.g003
was 4.0 days (range, 1–28 days). Of the 57 subjects, 46 (80.7%) had a toxicology consult service assisting in diagnosis and management. Only 2 individuals (4%) received dapsone either prior to (per report) or during their hospital admission. Approximately half of individuals (49.1%) required initial admission or transfer to an ICU due to their critical condition and need for more intensive monitoring. Acute renal injury with a 2-fold increase in the creatinine level occurred in 6 individuals (10.5%). The increase in creatinine among these 6 individuals ranged from 0.7–6.9 mg/dL. Few individuals (3; 5.3%) required dialysis due to severe acute renal failure.

Only 2 individuals died during the 20-year study period from loxoscelism. One individual was a previously healthy 54-year-old man who developed severe hemolysis 5 days after a

| Clinical Phenotype | Cases in Loxoscelism only cohort (n = 57), No. (%) | Cases in Entire Population, No. | Controls in Entire Population, No. | OR (95% CI) | p-value |
|--------------------|--------------------------------------------------|--------------------------------|-----------------------------------|-------------|---------|
| Rash and other nonspecific skin eruption | 18 (32%) | 57 | 2700 | 54 (27–110) | 1.5x10^{-28} |
| Toxic effect of venom | 48 (84%) | 51 | 2793 | 16745 (3714–130031) | 1.8x10^{-28} |
| Acquired hemolytic anemias | 29 (51%) | 32 | 2674 | 2459 (700–12541) | 2.0x10^{-27} |
| Superficial cellulitis and abscess | 16 (28%) | 65 | 2696 | 36 (18–75) | 2.1x10^{-23} |
| Sepsis and SIRS | 10 (18%) | 22 | 2869 | 57 (23–144) | 3.0x10^{-18} |
| Fever of unknown origin | 22 (39%) | 207 | 2484 | 17 (9–33) | 5.3x10^{-17} |
| Other anemias | 11 (19%) | 93 | 2674 | 39 (16–94) | 1.1x10^{-16} |
| Coagulation defects | 10 (18%) | 33 | 2790 | 33 (14–75) | 2.3x10^{-16} |
| Elevated white blood count | 8 (14%) | 20 | 2736 | 64 (22–186) | 8.1x10^{-15} |
| Malaise and fatigue | 15 (26%) | 113 | 2616 | 17 (8–35) | 1.1x10^{-14} |
| Hematuria | 8 (14%) | 25 | 2630 | 36 (14–88) | 3.1x10^{-14} |
| Disorders of fluid, electrolyte, and acid-base | 15 (26%) | 128 | 2632 | 12 (6–24) | 1.5x10^{-12} |
| Diseases of white blood cells | 9 (16%) | 41 | 2736 | 23 (9–52) | 3.7x10^{-13} |
| Erythematous conditions | 7 (12%) | 21 | 2765 | 44 (15–127) | 1.6x10^{-12} |
| Septicemia | 7 (12%) | 26 | 2790 | 26 (10–65) | 6.7x10^{-12} |
| Electolyte imbalance | 9 (16%) | 57 | 2632 | 20 (8–47) | 1.8x10^{-11} |
| Tachycardia | 8 (14%) | 44 | 2651 | 18 (7–40) | 1.3x10^{-10} |
| Hypopotassemia | 5 (9%) | 28 | 2632 | 22 (7–65) | 7.9x10^{-8} |
| Cardiac dyshrhythmias | 10 (18%) | 118 | 2651 | 7 (3–15) | 3.4x10^{-7} |
| Acute renal failure | 5 (9%) | 27 | 2812 | 14 (5–39) | 6.1x10^{-7} |
| Thrombocytopenia | 5 (9%) | 35 | 2790 | 12 (4–32) | 1.1x10^{-6} |
| Edema | 5 (9%) | 31 | 2825 | 13 (4–35) | 1.7x10^{-6} |
| Purpura and other hemorrhagic conditions | 5 (9%) | 38 | 2790 | 11 (4–28) | 2.2x10^{-6} |
| Renal failure | 5 (9%) | 35 | 2812 | 11 (3–29) | 6.1x10^{-6} |
| Respiratory abnormalities | 4 (7%) | 23 | 2838 | 12 (3–34) | 1.2x10^{-5} |
| Pleurisy, pleural effusion | 4 (7%) | 31 | 2735 | 11 (3–31) | 5.3x10^{-5} |
| Myalgia and myositis unspecified | 4 (7%) | 32 | 2839 | 12 (3–37) | 8.1x10^{-5} |
| Other symptoms of respiratory system | 12 (21%) | 229 | 2441 | 4 (2–8) | 8.2x10^{-5} |
| Hypotension | 4 (7%) | 31 | 2834 | 9 (3–26) | 1.2x10^{-4} |

OR: Odds Ratio; SIRS: Systemic inflammatory response syndrome

https://doi.org/10.1371/journal.pone.0174941.t002
witnessed spider bite. He proceeded to multi-system organ failure with hemodynamic instability, renal and respiratory failure with ultimate cardiac arrest. The other individual was a previously healthy 3-year-old girl who developed signs of systemic loxoscelism within 6 hours of witnessed spider envenomation. She progressed to significant hematuria, anemia, thrombocytopenia, disseminated intravascular coagulopathy and shock within 19 hours of the bite resulting in death.[4]

**Discussion**

This represents, to our knowledge, the largest cohort analyzed with moderate to severe loxoscelism to date. In contrast to prior published data consisting only of individuals with life-threatening hemolysis from severe loxoscelism[8], our cohort includes a wider phenotypic range consisting of all individuals with evidence of hemolysis. The large majority (70%) of individuals with systemic loxoscelism in our cohort were under 20 years of age. According to the 2014 annual report of the American Association of Poison Control Centers’ National Poison Data System, the majority (63%) of individuals who present in the United States with a brown recluse spider bite are 20 years or older. This suggests that although adults suffer from envenomation from brown recluse spiders more frequently (which was also seen in our data), children are subject to a much more severe reaction. Prior literature shows more frequent case reports of systemic loxoscelism occurring in pediatric individuals[4, 24–26], and this large retrospective review corroborates that children are at greater risk for systemic loxoscelism.

Hemolysis can occur in severe cases of loxoscelism[3], but may present differently than typical intravascular hemolysis. HGB is the most direct indicator of clinical severity in hemolytic disease[27] and its level can become extremely low (< 6 g/dL) in severe forms of loxoscelism, as seen in 15 (26%) of the individuals in our cohort. LDH is also known to be elevated during states of intravascular hemolysis[27] which was also demonstrated in this cohort with loxoscelism, whose average highest LDH was 3 times the upper limit of normal. Hyperbilirubinemia is also seen during hemolysis and can rise to > 4 mg/dL in severe acute hemolysis[27, 28], as was seen in our cohort of individuals. Haptoglobin is known to be decreased in periods of hemolysis[27]; however, our cohort only had 11 (19%) individuals with a haptoglobin less than normal and an average haptoglobin low within the normal range. Sterile tissue injury or infection can initiate a local inflammatory response that mobilizes a systemic acute phase reaction, resulting in the induction of genes encoding the acute phase plasma proteins, including haptoglobin.[29] Therefore, a state of inflammation from the brown recluse spider bite in many of the individuals may result in difficulty in interpretation of the haptoglobin level.[30]

In our review, it is important to note that the disease rarely progressed to renal failure. Only 6 individuals had a significant increase in creatinine level, 5 of which were identified with the PheWAS to have renal failure as well. Only 3 of these patients required dialysis. Furthermore, renal failure did not correspond with mortality in our series as the individuals who progressed to death did so in such a quick and extreme fashion that dialysis was not undertaken. Treatment of systemic loxoscelism is mainly supportive.[9] Steroids have been used to prevent kidney failure and hemolysis, but their efficacy is subject to debate.[9, 31] Other treatments that may be considered are dapsone, hyperbaric oxygen, and surgical excision.[9] Adverse side effects have been attributed to dapsone including hemolysis, anemia, and hyperbilirubinemia. [9] Only two individuals in our cohort received treatment with dapsone, both for short time periods. Although not statistically significant, one individual who received dapsone was an adult who developed severe hemolysis and subsequently died, whereas the other was a teenage male who suffered severe hemolysis that resolved. Omitting these individuals who received
dapsone, the remainder of the hemolysis within our cohort cannot be attributed to treatment patterns of dapsone use.

Literature on rates of DAT positivity in systemic loxoscelism is scant; several small case series have reported high rates of positive DAT.[7, 32] Our large case series confirms DAT is positive in more than 50% of severely affected individuals, although this does not necessarily correlate with severity of disease. These prior reports demonstrated both IgG and C3 on the red blood cell surface, as is seen in a portion of our cohort with loxoscelism. Our results support the hypothesis that the anemia in loxoscelism can result from direct toxin-mediated erythrocyte damage, complement-mediated immune destruction, or both. Autoimmune hemolytic anemia[33] as well as other immune-mediated illnesses[34] are known to be associated with Human Leukocyte Antigen (HLA) type. HLA-DQ6 has shown in a small case series to have a negative association with a positive DAT result in individuals with hemolysis[33]; whether our cohort is enriched for this genotype is unknown.

As with most PheWAS analyses based on billing codes, all statistically significant phenotypes were of increased prevalence in the case population. We found that the PheWAS analysis recapitulated the described phenotype for systemic loxoscelism, and also suggested additional phenotypes of concern. Through PheWAS, some significant phenotypes were directly related to the defined definition of loxoscelism, whereas other phenotypes were likely due to secondary effects or potentially factors increasing risk for the disease process. Phenotypes of loxoscelism strongly replicated include toxic effect of venom (OR 16745, 95% CI 3714–130031) and hemolytic anemia (OR 2459, 95% CI 700–12541). The phenotype “toxic effect of venom” is mapped to a single ICD-9 code, 989.5, which applies to bites of venomous snakes, lizards, ticks, and spiders. We also found that the PheWAS analysis reconfirmed other known clinical findings in loxoscelism that were not within our loxoscelism case definition. These included rash or other nonspecific skin eruption (OR 54, 95% CI 27–110), hematuria (OR 36, 95% CI 14–88), coagulation defects (OR 33, 95% CI 14–75), malaise and fatigue (OR 17, 95% CI 8–35), and fever of unknown origin (OR 17, 95% CI 9–33).

Although hematuria was significant in PheWAS, hemoglobinuria was not. Hematuria and hemoglobinuria are both known findings in systemic loxoscelism, with hematuria occurring almost invariably in severe disease.[35–39] Urine dipstick analysis for blood is typically the initial screening test for hematuria or hemoglobinuria. In subsequent testing, the presence of red blood cells on microscopic urinalysis are indicative of hematuria. However, if the blood is detectable on a dipstick with no or very few microscopically visible RBCs, hemoglobinuria or myoglobinuria is suggested.[40] It is possible that misclassification of these billing diagnosis codes occurred, resulting in a stronger phenotypic association with hematuria. We did note in our cohort that hematuria, sometimes gross hematuria, was a present in patients with very severe forms of loxoscelism.

Several phenotypes more likely to be secondary effects of loxoscelism were also found to be significant in the PheWAS analysis. In particular, there appears to be a strong signal for septicemia (OR 26, 95% CI 10–63), sepsis and systemic inflammatory response syndrome (OR 56, 95% CI 22–140)–suggesting that bacterial superinfection of the local wound site and/or iatrogenic infections are an important consideration in this population. There is also a strong signal for cardiac dysrhythmias (OR 7, 95% CI 3–14) and electrolyte imbalance (OR 20, 95% CI 8–46), suggesting that the systemic loxoscelism process or secondary effects (massive fluid resuscitation, renal failure, etc.) lead to significant issues requiring intensive medical management. With the well-defined phenotype captured by PheWAS analysis, it is possible to construct phenotype risk scores that could capture individuals that may not have been formally diagnosed; this remains the subject of future work.[41]
There are several limitations to our study. This study was undertaken at a single institution and may not be generalizable to others, especially institutions within other countries in North and South America where antivenom is an option for medical treatment. Although the use and efficacy of antivenom is controversial, with studies indicating potentially limited capacity of the medication to neutralize the systemic effects of loxoscelism due to delayed presentation of illness, further research in this area is needed.[42] Our case identification relied on the use of the word “loxoscelism” in clinical notes; this word is uncommon in the medical jargon and could be hypothetically misspelled. However, a preliminary investigation using the keywords “brown recluse” resulted in a large false positive rate. Another limitation is that many of the cases were referred to VUMC for tertiary-level care and had very little preceding or subsequent history in the SD, limiting our ability to evaluate for long term sequelae in sufferers of systemic loxoscelism. Most importantly, our retrospective chart review was limited by the fact that systemic loxoscelism is a clinical diagnosis that is made upon the presence of systemic symptoms, a cutaneous lesion consistent with a brown recluse spider bite, and clinical presentation and history. There is no confirmatory test for its diagnosis. We believe our criteria to require laboratory markers of hemolysis and documented diagnosis of loxoscelism was the most accurate approach to determining the true prevalence of loxoscelism within our institution. Furthermore, review was performed by physicians to ensure accuracy. More stringent criteria, such as requirement that the spider responsible for envenomation is captured and confirmed to be a brown recluse, would likely lead to a profound underestimation of the actual occurrence of systemic loxoscelism in endemic areas. Lastly, as the severity of loxoscelism occurs along a spectrum without a clear definition of what determines severe disease, we did not distinguish between moderate and severe loxoscelism, including in our cohort all individuals with systemic signs of hemolysis or disseminated intravascular coagulation, need for blood transfusion, or hemodynamic instability. This allowed for greater inclusion of individuals affected by the disease; however, it also led to increased variability in our phenotype.

In conclusion, systemic loxoscelism is a rare occurrence, but within a region endemic to brown recluse spiders, multiple individuals present yearly with moderate to severe loxoscelism. A portion of these individuals develops moderate to severe hemolysis. Although children and possibly African Americans appear to be at increased risk, it remains unclear what specific risk factors correlate with disease severity.

Author Contributions

Conceptualization: JD JLW.

Data curation: JRR VEK YD LB.

Formal analysis: LB JRR JLW.

Investigation: VEK YD LB JRR.

Methodology: JD JLW LB.

Project administration: JLW JRR.

Software: LB.

Supervision: JLW JD.

Writing – original draft: JRR.

Writing – review & editing: JRR VEK YD LB JD JLW.
References

1. Sams HH, Dunick CA, Smith ML, King LE Jr., Necrotic arachnidism. J Am Acad Dermatol. 2001; 44(4):561–73; quiz 73–6. Epub 2001/03/22. https://doi.org/10.1067/mjd.2001.112385 PMID: 11260528

2. Futrell JM. Loxoscelism. Am J Med Sci. 1992; 304(4):261–7. Epub 1992/10/01. PMID: 1415323

3. Murray LM, Seger DL. Hemolytic anemia following a presumptive brown recluse spider bite. J Toxicol Clin Toxicol. 1994; 32(4):451–6. Epub 1994/01/01. PMID: 8057405

4. Rosen JL, Dumitru JK, Langley EW, Meade Olivier CA. Emergency department death from systemic loxoscelism. Ann Emerg Med. 2012; 60(4):439–41. Epub 2012/02/07. https://doi.org/10.1016/j.annemergmed.2011.12.011 PMID: 22305333

5. Nance WE. Hemolytic anemia of necrotic arachnidism. Am J Med. 1961; 31:801–7. Epub 1961/11/01. PMID: 14473802

6. Williams ST, Khare VK, Johnston GA, Blackall DP. Severe intravascular hemolysis associated with brown recluse spider envenomation. A report of two cases and review of the literature. Am J Clin Pathol. 1995; 104(4):463–7. Epub 1995/10/01. PMID: 7572999

7. McDade J, Aygun B, Ware RE. Brown recluse spider (Loxosceles reclusa) envenomation leading to acute hemolytic anemia in six adolescents. The Journal of pediatrics. 2010; 156(1):155–7. Epub 2009/12/17. https://doi.org/10.1016/j.jpeds.2009.07.021 PMID: 20006769

8. Gehrie EA, Nian H, Young PP. Brown Recluse spider bite mediated hemolysis: clinical features, a possible role for complement inhibitor therapy, and reduced RBC surface glycophorin A as a potential biomarker of venom exposure. PloS one. 2013; 8(9):e76558. Epub 2013/10/03. PubMed Central PMCID: PMCPMC3785411. https://doi.org/10.1371/journal.pone.0076558 PMID: 24086749

9. Andersen RJ, Campoli J, Johar SK, Schumacher KA, Allison EJ Jr. Suspected brown recluse envenomation: a case report and review of different treatment modalities. The Journal of emergency medicine. 2011; 41(2):e31–7. Epub 2010/04/07. https://doi.org/10.1016/j.jemermed.2009.08.055 PMID: 20363581

10. de Oliveira KC, Goncalves de Andrade RM, Piazza RM, Ferreira JM Jr., van den Berg CW, Tambourgi DV. Variations in Loxosceles spider venom composition and toxicity contribute to the severity of envenomation. Toxicon. 2005; 45(4):421–9. Epub 2005/03/01. https://doi.org/10.1016/j.toxicon.2004.08.022 PMID: 15735963

11. Tambourgi DV, Pedrosa MF, de Andrade RM, Billington SJ, Griffiths M, van den Berg CW. Sphingomyelinases D induce direct association of C1q to the erythrocyte membrane causing complement mediated autologous haemolysis. Mol Immunol. 2007; 44(4):576–82. https://doi.org/10.1016/j.molimm.2006.02.002 PMID: 16540172

12. Gremski LH, Trevisan-Silva D, Ferrer VP, Matsubara FH, Wille AC, et al. Recent advances in the understanding of brown spider venoms: From the biology of spiders to the molecular mechanisms of toxins. Toxicon: official journal of the International Society on Toxinology. 2014; 83:91–120.

13. Tambourgi DV, Goncalves-de-Andrade RM, van den Berg CW. Loxoscelism: From basic research to the proposal of new therapies. Toxicon: official journal of the International Society on Toxinology. 2010; 56(7):1113–9.

14. Wright SW, Wrenn KD, Murray L, Seger D. Clinical presentation and outcome of brown recluse spider bite. Ann Emerg Med. 1997; 30(1):28–32. Epub 1997/07/01. PMID: 9209221

15. Mowry JB, Spyker DA, Brooks DE, McMillan N, Schauben JL. 2014 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 32nd Annual Report. Clinical toxicology (Philadelp hia, Pa). 2015; 53(10):962–1147. Epub 2015/12/02.

16. Swanson DL, Vetter RS. Bites of brown recluse spiders and suspected necrotic arachnidism. N Engl J Med. 2005; 352(7):700–7. Epub 2005/02/18. https://doi.org/10.1056/NEJMra041184 PMID: 15716844

17. Vetter RS. The distribution of brown recluse spiders in the southeastern quadrant of the United States in relation to loxoscelism diagnoses. Southern medical journal. 2009; 102(5):518–22. Epub 2009/04/18. https://doi.org/10.1097/SMJ.0b013e3181a0abb3 PMID: 19373143

18. Bush WS, Oetjens MT, Crawford DC. Unravelling the human genome-phenome relationship using phenome-wide association studies. Nature reviews Genetics. 2016; 17(3):129–45. https://doi.org/10.1038/nrg.2015.36 PMID: 26875678

19. Denny JC, Ritchie MD, Basford MA, Pulley JM, Bastarache L, Brown-Gentry K, et al. PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations. Bioinformatics. 2010; 26(9):1205–10. PubMed Central PMCID: PMCP2859332. https://doi.org/10.1093/bioinformatics/ btp126 PMID: 20335276

20. Denny JC, Bastarache L, Ritchie MD, Carroll RJ, Zink R, Mosley JD, et al. Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study.
21. Carroll RJ, Bastarache L, Denny JC. R PheWAS: data analysis and plotting tools for phenome-wide association studies in the R environment. Bioinformatics. 2014; 30(16):2375–6. PubMed Central PMCID: PMC4133579. https://doi.org/10.1093/bioinformatics/btu197 PMID: 2473291

22. Roden DM, Pulley JM, Basford MA, Bernard GR, Clayton EW, Balser JR, et al. Development of a large-scale de-identified DNA biobank to enable personalized medicine. Clinical pharmacology and therapeutics. 2008; 84(3):362–9. Epub 2008/05/27. PubMed Central PMCID: PMCPMC3763939. https://doi.org/10.1038/clpt.2008.89 PMID: 18500243

23. Team RC. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org/. 2015.

24. Said A, Hmiel P, Goldsmith M, Dietzen D, Hartman ME. Successful use of plasma exchange for profound hemolysis in a child with loxoscelism. Pediatrics. 2014; 134(5):e1464–7. Epub 2014/10/29. https://doi.org/10.1542/peds.2013-3338 PMID: 24733291

25. Levin C, Bonstein L, Lauterbach R, Mader R, Rozemman D, Koren A. Immune-mediated mechanism for thrombocytopenia after Loxosceles spider bite. Pediatric blood & cancer. 2014; 61(8):1466–8. Epub 2014/02/06.

26. Lane L, McCoppin HH, Dyer J. Acute generalized exanthematous pustulosis and Coombs-positive hemolytic anemia in a child following Loxosceles reclusa envenomation. Pediatric dermatology. 2011; 28(6):685–8. Epub 2011/11/16. https://doi.org/10.1111/j.1525-1470.2010.01302.x PMID: 22082464

27. Barcellini W, Fattizzo B. Clinical Applications of Hemolytic Markers in the Differential Diagnosis and Management of Hemolytic Anemia. Dis Markers. 2015; 2015:635670. Epub 2015/01/29. PubMed Central PMCID: PMCPMC4706896. https://doi.org/10.1155/2015/635670 PMID: 26819490

28. Berlin NI, Berk PD. Quantitative aspects of bilirubin metabolism for hematologists. Blood. 1981; 57(6):983–99. Epub 1981/06/01. PMID: 7225572

29. Wang Y, Kinzie E, Berger FG, Lim SK, Bauman H. Haptoglobin, an inflammation-inducible plasma protein. Redox report: communications in free radical research. 2001; 6(6):379–85. Epub 2002/02/28. https://doi.org/10.1179/135100010101536580 PMID: 11865981

30. Shih AW, McFarlane A, Verhovsek M. Haptoglobin testing in hemolysis: measurement and interpretation. American journal of hematology. 2014; 89(4):443–7. Epub 2014/05/09. PMID: 24809098

31. Forks TP. Brown recluse spider bites. J Am Board Fam Pract. 2000; 13(6):415–23. Epub 2000/12/16. PMID: 11117338

32. Lane DR, Youse JS. Coombs-positive hemolytic anemia secondary to brown recluse spider bite: a review of the literature and discussion of treatment. Cutis. 2004; 74(6):341–7. Epub 2005/01/25. PMID: 15663070

33. Wang-Rodriguez J, Rearden A. Reduced frequency of HLA-DQ6 in individuals with a positive direct antiglobulin test. Transfusion. 1996; 36(11–12):979–84. Epub 1996/11/01. PMID: 8937408

34. Gough SC, Simmonds MJ. The HLA Region and Autoimmune Disease: Associations and Mechanisms of Action. Current genomics. 2007; 8(7):453–65. Epub 2007/11/01. PubMed Central PMCID: PMCPMC2647156. https://doi.org/10.2174/138920207783591690 PMID: 19412418

35. Schenone H, Saavedra T, Rojas A, Villarroel F. [Loxoscelism in Chile. Epidemiologic, clinical and experimental studies]. Revista do Instituto de Medicina Tropical de Sao Paulo. 1989; 31(6):403–15. Epub 1989/11/01. PMID: 2577020

36. Rios JC, Perez M, Sanchez P, Bettini M, Mieres JJ, Paris E. [Prevalence and epidemiology of Loxosceles laeta bite. Analysis of consultations to a poison control center]. Revista medica de Chile. 2007; 135(9):1160–5. Epub 2007/12/08. https://doi.org/10.4137/CMBD.S11517 PMID: 15824833

37. Zambrano A, Gonzalez J, Callejas G. [Severe loxoscelism with lethal outcome. Report of one case]. Revista medica de Chile. 2005; 133(2):219–23. Epub 2005/04/13. https://doi.org/10.4137/CMBD.S11517 PMID: 15824833

38. Barretto OC, Satake M, Nonoyama K, Cardoso JL. The calcium-dependent protease of Loxosceles gaucho venom acts preferentially upon red cell band 3 transmembrane protein. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas. 2003; 36(3):309–13. Epub 2003/03/18. PMID: 12640494

39. Schenone H, Prata F. Arachnidism by Loxosceles laeta. Report of 40 cases of necrotic arachnidism. Arch Dermatol. 1961; 83:139–42. Epub 1961/01/01. PMID: 13747486

40. Veerreddy P. Hemoglobinuria misidentified as hematuria: review of discolored urine and paroxysmal nocturnal hemoglobinuria. Clinical medicine insights Blood disorders. 2013; 6:7–17. Epub 2013/01/01. PubMed Central PMCID: PMCPMC4222305. https://doi.org/10.4137/CMBD.S11517 PMID: 25512715
41. Bastarache L, Mosely J, Edwards T, Carroll R, Mo H, Wiley L, et al., editors. Complex diseases are associated with variation in Mendelian genes: A phenome-wide study using Human Phenotype Ontology and a population genotyped on the Exome BeadChip. American Society of Human Genetics; 2015; Baltimore, MD.

42. Pauli I, Puka J, Gubert IC, Minozzo JC. The efficacy of antivenom in loxoscelism treatment. Toxicon. 2006; 48(2):123–37. Epub 2006/07/01. https://doi.org/10.1016/j.toxicon.2006.05.005 PMID: 16808942